Claims for Patent: 9,879,224

Summary for Patent: 9,879,224

Title:	Label-free identification of stem cell-differentiated cells
Abstract:	Methods are disclosed for isolation of a stem-cell derived differentiated cell, which method entails illuminating an incident light onto a plurality of stem-cell derived cells that comprise at least an undifferentiated cell and a differentiated cell possessing a noncentrosymmetric structure, wherein the differentiated cell generates second-harmonic light from the incident light; and isolating the differentiated cell identified by the second-harmonic light. Devices for carrying out the methods are also provided.
Inventor(s):	Chan; James W. (Davis, CA), Lieu; Deborah (Davis, CA)
Assignee:	The Regents of the University of California (Oakland, CA) Lawrence Livermore National Security, LLC (Livermore, CA)
Application Number:	14/354,067
Patent Claims:	1. A method for sorting and isolating a stem-cell derived, stage-specific immature cardiomyocyte, comprising: (a) illuminating an incident light onto a plurality of stem-cell derived cells that comprise at least an undifferentiated cell and an immature cardiomyocyte possessing an intracellular noncentrosymmetric structure, wherein the immature cardiomyocyte generates second-harmonic light from the incident light; (b) identifying the stage of differentiation in the immature cardiomyocyte by detecting the intensity of the second-harmonic light generated by the immature cardiomyocyte; and (c) sorting and isolating the stage-specific immature cardiomyocyte identified in step (b), wherein the noncentrosymmetric structure is myosin. 2. The method of claim 1, wherein the immature cardiomyocyte is differentiated, in vitro, from a stem-cell wherein the duration of the differentiation is less than 180 days. 3. The system of claim 2, wherein the duration of the differentiation is less than 30 days. 4. The method of claim 2, wherein the stem-cell that produces the a stem-cell derived immature cardiomyocyte is of the group: an embryonic stem cell, an induced pluripotent stem cell, a multipotent stem cell, an oligopotent stem cell, or a unipotent stem cell. 5. The method of claim 1, wherein the incident light has a wavelength from about 700 nm to about 1500 nm. 6. The method of claim 1, wherein the incident light comprises pulses having a width of about 70 fs to about 10 ps. 7. The method of claim 1, wherein the incident light has a repetition rate from about 1 KHz to about 100 MHz. 8. The method of claim 1, wherein the cell is isolated in the absence of exogenous label or the cell is isolated in the absence of genetic modification of the cells. 9. The method of claim 8, wherein the exogenous label is a fluorescent label or a radioactive label. 10. The method of claim 1, further comprising suspending the cells in a medium prior to illuminating the incident light onto the cells. 11. The method of claim 10, wherein the medium comprises collagenase. 12. The method of claim 10, wherein the medium does not contain trypsin. 13. The method of claim 1, wherein the stem cell is a mammalian stem cell. 14. The method or population of claim 13, wherein the stem cell is of the group of a murine stem cell or a human stem cell. 15. The method of claim 1, wherein the stage of differentiation is identified by detecting low intensity second harmonic light. 16. The method of claim 1, wherein the stage of differentiation is identified by detecting high intensity second harmonic light.

Details for Patent 9,879,224

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2031-10-27